acrodermatitis chronica atrophicans: An acrodermatitis characterized by a chronically progressive course, leading to widespread atrophy of the skin. It is a clinical manifestation of Lyme borreliosis.
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
557745 |
1. Apply sex-specific ruleNone |
557745 |
2. Check conditionsNone |
557745 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
2 out of 7 registries used, show all original rules. |
68 |
4. Check minimum number of eventsNone |
68 |
5. Include endpointsNone |
68 |
6. Filter based on genotype QC (FinnGen only) |
60 |
Control definitions (FinnGen only)
- Control exclude
- L12_OTHERSKINSUBCUTIS
Extra metadata
- Level in the ICD hierarchy
- 4
- First used in FinnGen datafreeze
- DF2
- Parent code in ICD-10
- L90
- Name in latin
- Acrodermatitis chronica atrophicans
Similar endpoints
↥List of similar endpoints to
Acrodermatitis chronica atrophicans
based on the number of shared cases.
Similar with more cases:
- Atrophic disorders of skin
- Other disorders of skin and subcutaneous tissue
- Diseases of the skin and subcutaneous tissue
- Any operation in hilmo
- Any prescribed medicine buy
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 334 | 248 | 84 |
| Only index persons | 309 | 234 | 75 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.01 | 0.01 | 0.00 |
| Only index persons | 0.01 | 0.01 | 0.00 |
| Median age at first event (years) | |||
| Whole population | 62.27 | 64.11 | 57.42 |
| Only index persons | 62.64 | 64.30 | 57.46 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 60 | 39 | 21 |
| Unadjusted period prevalence (%) | 0.01 | 0.01 | 0.01 |
| Median age at first event (years) | 64.87 | 64.68 | 65.23 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
No data
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 62
- Matched controls
- 620
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
L90.4
ICD-10 Finland
Acrodermatitis chronica atrophicans
13423.3
84.4
61
*
L90.0
ICD-10 Finland
Lichen sclerosus et atrophicus
40.3
10.8
13
*
TQX10
NOMESCO Finland
Biopsy of skin and subcutaneous tissue
12.5
10.5
19
21
A69.2
ICD-10 Finland
Lyme disease
11.0
9.4
18
22
LFB00
NOMESCO Finland
Biopsy of vulva or perineum
34.5
7.4
9
*
L30.9
ICD-10 Finland
Dermatitis, unspecified
4.3
6.8
24
79
D07AD01
ATC
clobetasol; topical
4.7
6.3
18
50
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
11
18
7.17
4.86
1.1
1.2
1.22
1.14
g/l
0.29
11
18
11
18
7.17
4.86
1.1
1.2
0.27
0.23
g/l
0.64
11
18
24
110
2.93
3.83
1.6
1.3
31.18
38.55
iu/ml
—
6
44
9
21
4.82
3.13
1.6
1.2
—
—
—
0
0
5
10
5.33
2.11
1.0
1.2
—
—
—
0
0
19
102
2.24
2.05
1.6
1.3
1.34
13.77
u/ml
—
5
36
52
423
2.42
1.80
5.9
4.8
10.43
11.98
mm/h
0.60
47
380
7
28
2.69
1.50
11.7
9.7
26.29
25.51
mmol/l
—
7
28
10
46
2.40
1.49
9.1
8.1
1.15
1.44
mmol/l
—
10
46
13
70
2.08
1.36
2.8
4.7
217.46
249.02
u/l
1.18
13
65
19
124
1.77
1.14
2.3
2.8
0.72
0.98
e6/l
—
9
67
7
33
2.26
1.09
8.3
10.1
24.86
25.49
mmol/l
—
7
33
7
34
2.19
1.07
2.4
1.3
—
—
—
0
0
7
34
2.19
1.07
7.0
6.7
14.70
15.67
%
—
7
34
17
111
1.73
1.01
2.3
3.1
5.67
4.41
e6/l
—
6
55
12
71
1.86
0.97
2.1
2.6
6.42
7.35
umol/l
0.17
12
65
33
270
1.48
0.73
2.4
2.2
81.04
94.05
pmol/l
0.73
14
133
12
80
1.62
0.65
9.1
6.5
105.83
104.35
mmol/l
0.72
12
80
15
106
1.55
0.65
2.5
3.0
0.77
0.81
mmol/l
0.76
15
101
24
191
1.42
0.59
2.8
3.0
3.88
0.35
e6/l
0.45
16
137
6
40
1.55
0.53
7.5
10.1
0.45
0.71
%
—
6
40
6
40
1.55
0.53
7.5
10.2
1.40
1.41
%
—
6
40
7
48
1.52
0.49
2.3
2.1
—
—
—
0
0
22
180
1.34
0.44
3.8
2.4
67.59
57.05
u/l
0.34
22
165
27
228
1.33
0.44
3.5
3.2
—
—
—
0
0
5
32
1.61
0.43
6.8
2.4
0.98
1.23
%
—
5
32
0
15
0.00
0.42
0.0
1.3
—
—
—
0
0
5
34
1.51
0.41
1.6
1.4
—
—
—
0
0
37
329
1.31
0.41
8.8
6.6
12.16
11.03
umol/l
0.43
37
310
9
70
1.33
0.39
2.7
1.7
—
—
—
0
0
56
574
0.75
0.34
26.5
18.5
139.73
139.81
mmol/l
0.08
56
563
10
76
1.38
0.30
4.0
7.5
—
—
—
0
0
8
63
1.31
0.29
7.9
8.2
108.88
121.22
g/l
—
8
63
57
550
1.45
0.28
6.2
6.4
2.77
2.67
mmol/l
0.35
52
512
56
538
1.42
0.26
5.3
5.5
5.71
5.94
mmol/l
1.03
51
495
12
146
0.78
0.25
4.8
6.1
3.45
2.20
ug/l
0.31
12
124
18
208
0.81
0.25
4.3
4.5
1.54
9.94
mg/mmol
1.85
11
136
7
94
0.71
0.24
2.0
1.5
—
—
—
0
0
23
258
0.83
0.24
3.2
2.7
—
—
estimate
—
0
0
25
224
1.19
0.22
2.4
4.5
23.00
24.18
ng/l
0.03
15
166
0
11
0.00
0.21
0.0
1.5
—
—
—
0
0
0
10
0.00
0.21
0.0
1.3
—
—
—
0
0
0
10
0.00
0.21
0.0
1.3
—
—
—
0
0
0
10
0.00
0.21
0.0
1.1
—
16.71
—
0
10
0
10
0.00
0.21
0.0
1.5
—
—
—
0
0
0
12
0.00
0.21
0.0
4.1
—
—
—
0
0
0
12
0.00
0.21
0.0
1.0
—
—
—
0
0
15
128
1.23
0.21
2.2
2.1
—
—
—
0
0
0
14
0.00
0.20
0.0
3.6
—
123.43
—
0
14
0
14
0.00
0.20
0.0
1.5
—
—
—
0
0
0
14
0.00
0.20
0.0
2.3
—
90.73
—
0
6
6
51
1.20
0.20
5.7
3.4
81.67
73.29
ng/l
—
6
43
6
52
1.17
0.19
1.7
3.8
—
—
—
0
0
15
129
1.21
0.19
1.6
1.8
0.75
2.00
mg/l
—
10
106
7
57
1.26
0.19
2.4
2.2
—
—
—
0
0
8
67
1.22
0.17
7.1
8.2
1.16
1.78
mmol/l
—
8
57
8
68
1.20
0.17
8.1
8.0
5.31
5.04
kpa
—
8
68
56
544
1.30
0.16
5.7
5.4
4.70
4.62
mmol/l
0.23
50
505
54
523
1.25
0.15
4.9
4.5
1.10
1.26
mmol/l
1.25
48
475
47
451
1.17
0.15
13.4
8.6
76.98
80.89
u/l
0.27
47
421
5
43
1.18
0.10
2.6
4.9
1.24
1.22
mmol/l
—
5
37
7
67
1.05
0.08
2.9
1.7
—
—
—
0
0
56
546
1.26
0.08
22.9
15.7
24.36
21.36
mg/l
0.17
46
440
55
541
1.15
0.07
5.7
5.4
1.60
1.50
mmol/l
0.69
49
496
11
103
1.08
0.02
3.8
2.5
2.45
2.39
g/l
0.16
11
91
10
94
1.08
0.01
2.7
1.8
—
—
—
0
0
20
194
1.05
0.00
3.5
3.6
2923.53
974.12
ng/l
0.58
15
165
10
98
1.02
0.00
1.5
1.2
—
—
—
0
0
11
109
1.01
0.00
3.9
2.5
13.28
14.33
umol/l
0.18
11
100
30
302
0.99
0.00
3.3
2.7
—
—
—
0
0
6
60
1.00
0.00
1.5
1.3
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.5
—
104.83
—
0
6
0
9
0.00
-0.00
0.0
1.6
—
—
—
0
0
0
8
0.00
-0.00
0.0
6.9
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.8
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.9
—
180.00
—
0
8
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
(40770918) von Willebrand factor (vWf).activity actual/normal in Platelet poor plasma by Immunoassay
0
5
0.00
-0.00
0.0
3.2
—
106.60
—
0
5
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.4
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.5
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
3.5
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
276.92
—
0
5
0
6
0.00
-0.00
0.0
1.8
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.8
—
—
—
0
0
Mortality – FinRegistry
↥Association
Association between endpoint L12_ACRODERMATITIS and mortality.
Females
No dataMales
No dataMortality risk
Mortality risk for people of age
years, who have L12_ACRODERMATITIS.| N-year risk | Females | Males |
|---|---|---|
| 1 | No data | No data |
| 5 | No data | No data |
| 10 | No data | No data |
| 15 | No data | No data |
| 20 | No data | No data |
Relationships between endpoints
↥Index endpoint: L12_ACRODERMATITIS – Acrodermatitis chronica atrophicans
GWS hits: -
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data